Pazopanib
Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: GW 786034, GW786034B, pazopanib HCl, pazopanib hydrochloride, votrient
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Pazopanib is an ofp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2009. Its mechanism of action is classified as Cytochrome P450 2C8 Inhibitors, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A4 Inhibitors. DrugCentral lists 112 molecular targets, including CA12, KIT and PDGFRB. Recorded indications include Renal cell carcinoma and Sarcoma of soft tissue.
- Approval status: ofp (first approved 2009 by the FDA).
- Drug class: Kinase Inhibitor.
- Mechanism of action: Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inhibitors.
- Molecular targets: CA12, KIT, PDGFRB and PDGFRA (112 listed in DrugCentral).
- Indications: Renal cell carcinoma and Sarcoma of soft tissue.
- ATC code: L01EX03 (Other protein kinase inhibitors).
- Molecular formula: C21H23N7O2S; molecular weight 437.52 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Renal cell carcinoma
- Sarcoma of soft tissue
Contraindications (30)
- Acute hemorrhage
- Acute Thromboembolic Stroke
- Angina pectoris
- Cardiovascular event risk
- Cerebral hemorrhage
- Congenital long QT syndrome
- Diarrhea
- Drug-induced hepatitis
- Gastrointestinal fistula
- Gastrointestinal hemorrhage
- Gastrointestinal perforation
- Hepatic failure
- Hyperbilirubinemia
- Hypertensive disorder
- Hypertensive urgency
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Hypothyroidism
- Impaired wound healing
- Liver function tests abnormal
- Myocardial infarction
- Pancreatitis
- Pregnancy, function
- Prolonged QT interval
- Proteinuria
- Surgical procedure
- Thromboembolic disorder
- Torsades de pointes
- UGT1A1*28 polymorphism
Mechanism & targets
| Mechanism of action (MoA) | Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inhibitors; Protein Kinase Inhibitors |
|---|---|
| Established pharmacologic class | Kinase Inhibitor |
Molecular targets (112)
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2010-06-14 | EMA | — | — | |
| 2009-10-19 | FDA | — | NOVARTIS PHARMS CORP |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01EX03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: HLA-B · Informative PGx
- FDA label: HLA-B, UGT1A1 · Informative PGx
- HCSC label: HLA-B · Actionable PGx
- Swissmedic label: HLA-B · Actionable PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Malignant neoplasm progression | 2294.6 |
| Hair colour changes | 1592.9 |
| Death | 1159.6 |
| Diarrhoea | 1056.7 |
| Disease progression | 542.6 |
| Metastases to lung | 437.5 |
| Decreased appetite | 425.5 |
| Hypertension | 394.4 |
| Palmar-plantar erythrodysaesthesia syndrome | 369.4 |
| Product use in unapproved indication | 363.8 |
| Fatigue | 339.7 |
| Nausea | 315.2 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Pazopanib is on its molecule page.
| Molecular formula | C21H23N7O2S |
|---|---|
| Molecular weight | 437.52 g/mol |
| CAS number | 444731-52-6 |
| InChIKey | CUIHSIWYWATEQL-UHFFFAOYSA-N |
| PubChem CID | 10113978 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Pazopanib used for?
DrugCentral lists the following indications for Pazopanib: Renal cell carcinoma and Sarcoma of soft tissue.
How does Pazopanib work?
Pazopanib is classified as Cytochrome P450 2C8 Inhibitors, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A4 Inhibitors; its molecular targets in DrugCentral include CA12, KIT (inhibitor), PDGFRB (inhibitor) and PDGFRA (inhibitor).
When was Pazopanib first approved?
Pazopanib was first approved by the FDA in 2009.
What drug class does Pazopanib belong to?
Pazopanib is in the Kinase Inhibitor class.
What is the chemical formula of Pazopanib?
Pazopanib has the molecular formula C21H23N7O2S and a molecular weight of 437.52 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4118 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201733 — compound record and bioactivity
- PubChem CID 10113978 — chemical identifiers
- DrugBank DB06589 — drug record
- FDA UNII 7RN5DR86CK — substance identity
- DailyMed: FDA labels for Pazopanib — current prescribing information (label search)
- UniProt O43570 (CA12) — target protein
- UniProt P10721 (KIT) — target protein
- UniProt P09619 (PDGFRB) — target protein
- UniProt P16234 (PDGFRA) — target protein
- UniProt P07333 (CSF1R) — target protein
- UniProt Q16790 (CA9) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.